Pepscan is a biotech company developing novel therapeutic options for cancer and immunological diseases. Our ambition is to be world-leader in protein mimicry technologies and to apply these technologies for discovery of therapeutic anti-GPCR monoclonal antibodies and improved therapeutic peptides.
Synthetic immunogens, mimicking the biologically relevant parts of target GPCR's, have proven highly successful in yielding functional antibodies.
CLIPS™ technology has shown to improve the activity and stability of peptides, and thus provides great opportunities for new therapeutic peptide drugs.
CLIPS™ Epitope Mapping provides uniquely detailed binding information on the level of single amino acids. This offers IP opportunities for your antibodies.
Epitope mapping services are available through Pepscan PRESTO.
Pepscan's technologies are also applied in a range of fee-for-service products. These incude custom peptide synthesis and epitope mapping services.
Custom peptide services are available through Pepscan PRESTO.